機関投資家は2Qの業績が好調で 利益予測を維持した中で ヴェルテックス製薬の株を増やしました Institutional investors increased stakes in Vertex Pharmaceuticals amid strong Q2 results and maintained earnings guidance.

機関投資家は第2四半期にVertex Pharmaceuticalsの株式を増やし,Hanson & Doremusは200株を追加し,Alpine Bank Wealth Managementは53.3%のポジションを高めました. Institutional investors increased their stakes in Vertex Pharmaceuticals in Q2, with Hanson & Doremus adding 200 shares and Alpine Bank Wealth Management boosting its position by 53.3%. 同社は,第2四半期に堅実な業績を報告し,株当たり4.52ドル,収益は11.3%増の29億4千万ドルとなり,全年度の利益予測を維持した. The company reported strong Q2 results, earning $4.52 per share, up 11.3% in revenue to $2.94 billion, and maintaining its full-year earnings guidance. 分析官は,株を493.81ドルの目標で『モデレート・バイヤー』とみなす. Analysts rate the stock a "Moderate Buy" with a $493.81 target. 株式は2025年9月29日に385.73ドルで開業し,市場キャピタルは989億米ドルであった. The stock opened at $385.73 on September 29, 2025, with a market cap of $98.90 billion.